These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Martínez-González J; Raposo B; Rodríguez C; Badimon L Arterioscler Thromb Vasc Biol; 2001 May; 21(5):804-9. PubMed ID: 11348878 [TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407 [TBL] [Abstract][Full Text] [Related]
5. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. Laufs U; Liao JK J Biol Chem; 1998 Sep; 273(37):24266-71. PubMed ID: 9727051 [TBL] [Abstract][Full Text] [Related]
6. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Endres M; Laufs U; Huang Z; Nakamura T; Huang P; Moskowitz MA; Liao JK Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8880-5. PubMed ID: 9671773 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Mehta JL; Li DY; Chen HJ; Joseph J; Romeo F Biochem Biophys Res Commun; 2001 Dec; 289(4):857-61. PubMed ID: 11735125 [TBL] [Abstract][Full Text] [Related]
8. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Hernández-Perera O; Pérez-Sala D; Navarro-Antolín J; Sánchez-Pascuala R; Hernández G; Díaz C; Lamas S J Clin Invest; 1998 Jun; 101(12):2711-9. PubMed ID: 9637705 [TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. Weber C; Erl W; Weber KS; Weber PC J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917 [TBL] [Abstract][Full Text] [Related]
10. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Kolyada AY; Fedtsov A; Madias NE Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849 [TBL] [Abstract][Full Text] [Related]
12. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
15. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905 [TBL] [Abstract][Full Text] [Related]
16. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Qin W; Infante J; Wang SR; Infante R Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634 [TBL] [Abstract][Full Text] [Related]
17. Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Li D; Singh RM; Liu L; Chen H; Singh BM; Kazzaz N; Mehta JL Cardiovasc Res; 2003 Jan; 57(1):238-43. PubMed ID: 12504834 [TBL] [Abstract][Full Text] [Related]
18. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Luan Z; Chase AJ; Newby AC Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370 [TBL] [Abstract][Full Text] [Related]
19. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801 [TBL] [Abstract][Full Text] [Related]